Synaptogenix Inc (SNPX)

[InTheTrenches]

For those who are concerned that ONLY treating moderate-to-severe AD patients will limit the upside, here are my very conservative numbers:

My estimate: 1 to 1.5 million US citizens have moderate-to-severe AD (~6M US citizens are estimated to have all stages of AD).

If market penetration of Bryostatin is only half, that is 500,000-750,000 patients treated per year.

If Bryostatin still controls 100% of the drug, I believe a $5,000/pt/yr profit is doable.

Annual PROFIT = $2.5B-$3.75B/yr

X 15 PE = market cap of $37.5B-56.25B